CN112336914A - Sodium alginate composite gel and preparation method thereof - Google Patents
Sodium alginate composite gel and preparation method thereof Download PDFInfo
- Publication number
- CN112336914A CN112336914A CN202011169853.XA CN202011169853A CN112336914A CN 112336914 A CN112336914 A CN 112336914A CN 202011169853 A CN202011169853 A CN 202011169853A CN 112336914 A CN112336914 A CN 112336914A
- Authority
- CN
- China
- Prior art keywords
- sodium alginate
- composite gel
- gel
- alginate composite
- gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 title claims abstract description 83
- 239000000661 sodium alginate Substances 0.000 title claims abstract description 83
- 235000010413 sodium alginate Nutrition 0.000 title claims abstract description 83
- 229940005550 sodium alginate Drugs 0.000 title claims abstract description 83
- 239000002131 composite material Substances 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 238000001879 gelation Methods 0.000 title description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000022 bacteriostatic agent Substances 0.000 claims abstract description 31
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 29
- 229960001631 carbomer Drugs 0.000 claims abstract description 29
- 239000008367 deionised water Substances 0.000 claims abstract description 29
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 29
- 229920002643 polyglutamic acid Polymers 0.000 claims abstract description 29
- 235000012907 honey Nutrition 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 20
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 15
- 238000004132 cross linking Methods 0.000 claims abstract description 15
- 239000000600 sorbitol Substances 0.000 claims abstract description 15
- 238000005520 cutting process Methods 0.000 claims abstract description 7
- 230000001678 irradiating effect Effects 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 39
- 229920001282 polysaccharide Polymers 0.000 claims description 23
- 239000005017 polysaccharide Substances 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 14
- 230000008961 swelling Effects 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 12
- 241001530056 Athelia rolfsii Species 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- -1 N-acetylmuramyl polysaccharide Chemical class 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- 238000010894 electron beam technology Methods 0.000 claims description 4
- 238000001746 injection moulding Methods 0.000 claims description 2
- 230000035876 healing Effects 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 7
- 239000003431 cross linking reagent Substances 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 6
- 239000003999 initiator Substances 0.000 abstract description 3
- 238000005213 imbibition Methods 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 87
- 206010052428 Wound Diseases 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 230000003385 bacteriostatic effect Effects 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002522 swelling effect Effects 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000221696 Sclerotinia sclerotiorum Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a sodium alginate composite gel and a preparation method thereof, belonging to the technical field of medical consumables. The sodium alginate composite gel is prepared from the following raw materials in percentage by mass: 1-8% of sodium alginate, 0.2-1% of bacteriostatic agent, 1-8% of gamma-polyglutamic acid, 1-5% of honey, 0.1-2% of carbomer, 1-16% of sorbitol, 0.1-2.5% of pH regulator and the balance of deionized water. Preparing a composite gel raw material solution by a series of processes, defoaming, injecting, irradiating, crosslinking and cutting to obtain the sodium alginate composite gel. The sodium alginate composite gel prepared by the invention has the functions of imbibition, bacteriostasis and healing promotion, adopts a normal-temperature irradiation crosslinking method, does not need to additionally add a crosslinking agent and an initiator, has safe components and simple process, is colorless and transparent, is convenient for observing the wound condition from time to time, and is suitable for skin surface wound care.
Description
Technical Field
The invention relates to the technical field of medical consumables, in particular to a sodium alginate composite gel and a preparation method thereof.
Background
When skin is damaged, bleeding often occurs, and the integrity of the skin as a protective barrier is damaged, so that the bleeding wound surface can be quickly and effectively stopped within a short time when the skin is damaged, and the three key links of wound treatment are prevention of wound pollution and quick wound repair. Dressings are indispensable medical supplies, and the functions of ideal medical dressings should include protecting wounds from bacterial infection, accelerating wound healing, and providing, or retaining moisture at wounds, etc. The traditional dressing combines sterile gauze and external antibiotics, the gauze is easy to adhere to skin wound tissues in the using process, and the dressing change often breaks new epithelium and granulation tissues to cause secondary bleeding, so that the dressing is not favorable for wound healing. In recent years, a series of novel medical wound dressings have appeared based on the theory of moist healing, and high attention has been paid to various fields due to the practicability and necessity thereof. The novel medical dressing comprises various forms such as a film type, a foam type, a gel type and the like. Gel-type dressings almost integrate the various properties of ideal dressings, such as: the wound exudate can be absorbed and controlled, and the air permeability and the moisture permeability are good; the biocompatibility is good, the cytotoxicity is low, and local stimulation and anaphylactic reaction are avoided; the wound can be tightly attached without adhering, the wound is easy to take off, and the secondary wound can be avoided; fourthly, the wound healing condition can be observed transparently, and the medicine or the skin active ingredient can be loaded to promote the wound healing; can prevent invasion of exogenous microorganisms and other harmful substances, and effectively protect the wound. Therefore, gel dressings are an extremely important and promising class of polymeric materials.
The preparation method of the gel mainly comprises a chemical method, a freezing method and a radiation method. Gels prepared by conventional chemical synthesis methods require the use of chemical cross-linking agents and initiators, and the residual substances are harmful to the skin and wound surface. The gel prepared by the freezing method does not leave harmful substances, but has high preparation environment requirements, the lowest freezing temperature reaches-20 ℃, the preparation period is long, repeated freezing is generally carried out for 3-5 times, the process is complicated, and the equipment requirements are high. The irradiation method can provide a large amount of energy in a short time, so that reactants can quickly react to reach the required crosslinking degree, and a crosslinking agent and an initiator are not used. In-situ gel prepared from single sodium alginate needs to be added with calcium salt as a cross-linking agent, is safe and nontoxic, but the uniformity of the prepared gel is difficult to ensure, and the process conditions are harsh.
Disclosure of Invention
The invention aims to provide a sodium alginate composite gel which is prepared by an irradiation crosslinking method, does not need to add a crosslinking agent additionally, has simple components, good biocompatibility and excellent water absorption, can absorb a large amount of wound exudate, and has the functions of absorbing and permeating, inhibiting bacteria and promoting healing.
In order to achieve the purpose, the sodium alginate composite gel provided by the invention is prepared from the following raw materials in percentage by mass: 1-8% of sodium alginate, 0.2-1% of bacteriostatic agent, 1-8% of gamma-polyglutamic acid, 1-5% of honey, 0.1-2% of carbomer, 1-16% of sorbitol, 0.1-2.5% of pH regulator and the balance of deionized water.
Further, the bacteriostatic agent is an N-acetylmuramyl polysaccharide hydrolase-sclerotium rolfsii gum compound.
Further, the relative molecular weight of the gamma-polyglutamic acid is between 50 and 150 ten thousand.
Further, the thickness of the sodium alginate composite gel is 0.1-0.5 cm.
Further, the preparation method of the bacteriostatic agent in the sodium alginate composite gel comprises the following steps: mixing N-acetylmuramic polysaccharide hydrolase and sclerotium rolfsii gum according to the weight ratio of 1: 2-1: 4 to obtain a mixture, dissolving the mixture in a sodium phosphate buffer solution with the concentration of 0.1mol/L, pH of 8.0-9.0, wherein the weight-volume ratio of the mixture to the sodium phosphate buffer solution is 1 (10-20) g/mL, incubating for 1h at room temperature, freeze-drying at-70 ℃, placing the freeze-dried sample in a sealed glass dryer with a saturated KBr solution at the bottom, and placing for 8-12 days at the temperature of 60 ℃ and the relative humidity of 80% to obtain the N-acetylmuramic polysaccharide hydrolase-sclerotium rolfsii gum compound.
Further, the preparation method of the sodium alginate composite gel comprises the following steps: s1: taking a proper amount of deionized water, uniformly scattering carbomer powder while stirring, standing, and naturally swelling for 24 hours to obtain a carbomer solution; s2: respectively dissolving sodium alginate, gamma-polyglutamic acid and a bacteriostatic agent by using a proper amount of deionized water, then mixing with the carbomer solution obtained in S1, adding sorbitol, honey and the balance of deionized water, stirring uniformly under a vacuum condition, defoaming, and adjusting the pH to 5.5-7.0 by using a pH regulator to obtain a sodium alginate composite gel raw material solution; s3: and (5) defoaming, injection molding, irradiation crosslinking and cutting the composite gel raw material liquid obtained in the step (S2) to obtain the sodium alginate composite gel.
Such pH adjusters are well known to those skilled in the art, such as sodium dihydrogen phosphate, disodium hydrogen phosphate, triethanolamine, sodium hydroxide, and the like.
Furthermore, the irradiation crosslinking manner in step S3 is60And irradiating the Co-gamma rays or the high-energy electron beams with the irradiation dose of 10-50 kGy.
The invention has the following beneficial effects:
(1) the N-acetylmuramic polysaccharide hydrolase-sclerotium rolfsii gel compound prepared by a specific method is used as a bacteriostatic agent, so that the bacteriostatic effect can be accelerated, the broad-spectrum bacteriostatic activity of the bacteriostatic agent is enhanced, and the prepared sodium alginate composite gel has excellent bacteriostatic performance.
(2) The main active ingredients of the invention are selected from sodium alginate, gamma-polyglutamic acid, honey and bacteriostatic agent (N-acetylmuramic polysaccharide hydrolase-sclerotium rolfsii gum compound) which are natural sources to be combined, and the invention has the characteristics of safety, no toxicity and good biocompatibility, and the sodium alginate and the gamma-polyglutamic acid can improve excellent film forming property, moisture retention property, water locking property and swelling property, and are beneficial to absorbing and controlling wound exudate; the gamma-polyglutamic acid and honey have good antioxidant activity and wound repair performance; the honey, the N-acetylmuramic polysaccharide hydrolase and the sclerotium rolfsii gum are compounded to provide excellent bacteriostatic effect. Therefore, the compounding of the components with various natural sources improves the functions of absorption, permeation, bacteriostasis and healing promotion of the gel.
(3) The sodium alginate composite gel prepared by the method has good mechanical property and is convenient to stick and tear; the gel is stable and controllable in quality, colorless and transparent, light and thin in thickness, comfortable to use and capable of observing the wound healing condition more clearly when stored at normal temperature; and (4) preparing the sodium alginate composite gel by adopting an irradiation crosslinking method, without adding a crosslinking agent, without adding a washing or purifying process after crosslinking, and the sodium alginate composite gel has simple components and process, is easy for large-scale production, and has excellent effects of absorbing and permeating, moisturizing, inhibiting bacteria and promoting healing.
Drawings
FIG. 1 is a schematic diagram of efficacy test 2 of a sodium alginate composite gel according to the present invention, showing the bacteriostatic activity of a bacteriostatic activity test sample on Escherichia coli;
FIG. 2 is a schematic diagram of an efficacy test 2 of a sodium alginate composite gel according to the present invention, showing an inhibitory rate of a bacteriostatic activity test sample on Staphylococcus aureus;
Detailed Description
Example 1
The sodium alginate composite gel is prepared from the following raw materials in mass number: 1g of sodium alginate, 0.6g of bacteriostatic agent, 8g of gamma-polyglutamic acid (the relative molecular weight is 50 ten thousand), 1g of honey, 1.7g of carbomer, 9g of sorbitol, 2g of pH regulator and 100g of deionized water.
The bacteriostatic agent is an N-acetylmuramic polysaccharide hydrolase-sclerotium rolfsii gum compound, and the preparation method comprises the following steps: mixing N-acetylmuramic polysaccharide hydrolase and sclerotium rolfsii gum according to the weight ratio of 1:2 to obtain a mixture, dissolving the mixture in a sodium phosphate buffer solution with the concentration of 0.1mol/L, pH being 8.5, wherein the weight-volume ratio of the mixture to the sodium phosphate buffer solution is 1:10 g/mL, incubating for 1h at room temperature, freeze-drying at-70 ℃, placing a freeze-dried sample in a sealed glass dryer with a saturated KBr solution at the bottom, and placing for 10 days at the temperature of 60 ℃ and the relative humidity of 80% to obtain the chitosan oligosaccharide-based antibacterial peptide.
The preparation method of the sodium alginate composite gel comprises the following steps:
s1: taking a proper amount of deionized water, uniformly scattering 1.7g of carbomer powder while stirring, standing, and naturally swelling for 24 hours to obtain a carbomer solution;
s2: dissolving 1g of sodium alginate, 8g of gamma-polyglutamic acid and 0.6g of bacteriostatic agent by using a proper amount of deionized water respectively, then mixing with the carbomer solution obtained in S1, adding 9g of sorbitol, 1g of honey and the balance of deionized water, stirring uniformly and defoaming under a vacuum condition, and adjusting the pH to 5.5-7.0 by using a pH regulator to obtain a sodium alginate composite gel raw material solution;
s3: defoaming and molding the composite gel raw material liquid obtained in the step S2 at a dosage of 10kGy60Performing irradiation crosslinking and slitting under Co-gamma rayObtaining the sodium alginate composite gel with the thickness of 0.1 cm.
Example 2
The sodium alginate composite gel is prepared from the following raw materials in mass number: 7g of sodium alginate, 0.8g of bacteriostatic agent, 1g of gamma-polyglutamic acid (the relative molecular weight is 150 ten thousand), 2g of honey, 2g of carbomer, 7g of sorbitol, 2.5g of pH regulator and 100g of deionized water.
The bacteriostatic agent is an N-acetylmuramic polysaccharide hydrolase-sclerotium rolfsii gum compound, and the preparation method comprises the following steps: mixing N-acetylmuramic polysaccharide hydrolase and sclerotium rolfsii gum according to the weight ratio of 1:4 to obtain a mixture, dissolving the mixture in a sodium phosphate buffer solution with the concentration of 0.1mol/L, pH being 8.0, wherein the weight-volume ratio of the mixture to the sodium phosphate buffer solution is 1:15 g/mL, incubating for 1h at room temperature, freeze-drying at-70 ℃, placing a freeze-dried sample in a sealed glass dryer with a saturated KBr solution at the bottom, and placing for 12 days at the temperature of 60 ℃ and the relative humidity of 80% to obtain the chitosan oligosaccharide-based antibacterial peptide.
The preparation method of the sodium alginate composite gel comprises the following steps:
s1: taking a proper amount of deionized water, uniformly scattering 2g of carbomer powder while stirring, standing, and naturally swelling for 24 hours to obtain a carbomer solution;
s2: respectively dissolving 7g of sodium alginate, 1g of gamma-polyglutamic acid and 0.8g of bacteriostatic agent by using a proper amount of deionized water, then mixing with the carbomer solution obtained in S1, adding 7g of sorbitol, 2g of honey and the balance of deionized water, stirring uniformly and defoaming under a vacuum condition, and adjusting the pH to 5.5-7.0 by using a pH regulator to obtain a sodium alginate composite gel raw material solution;
s3: and (4) defoaming and molding the composite gel raw material liquid obtained in the step (S2), performing irradiation crosslinking under a high-energy electron beam with the dosage of 50kGy, and cutting to obtain the sodium alginate composite gel with the thickness of 0.5 cm.
Example 3
The sodium alginate composite gel is prepared from the following raw materials in mass number: 5g of sodium alginate, 0.2g of bacteriostatic agent, 6g of gamma-polyglutamic acid (the relative molecular weight is 80 ten thousand), 5g of honey, 1g of carbomer, 1g of sorbitol, 1.5g of pH regulator and 100g of deionized water.
The bacteriostatic agent is an N-acetylmuramic polysaccharide hydrolase-sclerotium rolfsii gum compound, and the preparation method comprises the following steps: mixing N-acetylmuramic polysaccharide hydrolase and sclerotium rolfsii gum according to the weight ratio of 1:2.5 to obtain a mixture, dissolving the mixture into a sodium phosphate buffer solution with the concentration of 0.1mol/L, pH of 9.0, wherein the weight-volume ratio of the mixture to the sodium phosphate buffer solution is 1:20 g/mL, incubating for 1h at room temperature, freeze-drying at-70 ℃, placing a freeze-dried sample in a sealed glass dryer with a saturated KBr solution at the bottom, and placing for 8 days at the temperature of 60 ℃ and the relative humidity of 80% to obtain the chitosan oligosaccharide-chitosan hydrogel.
The preparation method of the sodium alginate composite gel comprises the following steps:
s1: taking a proper amount of deionized water, uniformly scattering 1g of carbomer powder while stirring, standing, and naturally swelling for 24 hours to obtain a carbomer solution;
s2: respectively dissolving 5g of sodium alginate, 6g of gamma-polyglutamic acid and 0.2g of bacteriostatic agent by using a proper amount of deionized water, then mixing with the carbomer solution obtained in S1, adding 1g of sorbitol, 5g of honey and the balance of deionized water, stirring uniformly and defoaming under a vacuum condition, and adjusting the pH to 5.5-7.0 by using a pH regulator to obtain a sodium alginate composite gel raw material solution;
s3: defoaming and molding the composite gel raw material liquid obtained in the step S2 at a dosage of 30kGy60And (3) carrying out irradiation crosslinking under Co-gamma rays, and cutting to obtain the sodium alginate composite gel with the thickness of 0.3 cm.
Example 4
The sodium alginate composite gel is prepared from the following raw materials in mass number: 8g of sodium alginate, 1g of bacteriostatic agent, 4g of gamma-polyglutamic acid (the relative molecular weight is 100 ten thousand), 3g of honey, 0.1g of carbomer, 16g of sorbitol, 0.1g of pH regulator and 100g of deionized water.
The bacteriostatic agent is an N-acetylmuramic polysaccharide hydrolase-sclerotium rolfsii gum compound, and the preparation method comprises the following steps: mixing N-acetylmuramic polysaccharide hydrolase and sclerotium rolfsii gum according to the weight ratio of 1:3 to obtain a mixture, dissolving the mixture in a sodium phosphate buffer solution with the concentration of 0.1mol/L, pH being 8.5, wherein the weight-volume ratio of the mixture to the sodium phosphate buffer solution is 1:18 g/mL, incubating for 1h at room temperature, freeze-drying at-70 ℃, placing a freeze-dried sample in a sealed glass dryer with a saturated KBr solution at the bottom, and placing for 9 days at the temperature of 60 ℃ and the relative humidity of 80% to obtain the chitosan oligosaccharide-based antibacterial peptide.
The preparation method of the sodium alginate composite gel comprises the following steps:
s1: taking a proper amount of deionized water, uniformly scattering 0.1g of carbomer powder while stirring, standing, and naturally swelling for 24 hours to obtain a carbomer solution;
s2: respectively dissolving 8g of sodium alginate, 4g of gamma-polyglutamic acid and 1g of bacteriostatic agent by using a proper amount of deionized water, then mixing with the carbomer solution obtained in S1, adding 16g of sorbitol, 3g of honey and the balance of deionized water, uniformly stirring and defoaming under a vacuum condition, and adjusting the pH to 5.5-7.0 by using a pH regulator to obtain a sodium alginate composite gel raw material solution;
s3: and (4) defoaming and molding the composite gel raw material liquid obtained in the step (S2), performing irradiation crosslinking under a high-energy electron beam with the dosage of 20kGy, and cutting to obtain the sodium alginate composite gel with the thickness of 0.4 cm.
In order to better illustrate the beneficial effects of the sodium alginate composite gel, the following comparative examples are provided, and efficacy tests are carried out.
Comparative example 1
Compared with the embodiment 1, the composite gel has the advantages that the sodium alginate is replaced by the same amount of the gamma-polyglutamic acid, the sodium alginate is not contained, the amount of the gamma-polyglutamic acid is 9g, other components and the content are not changed, and the preparation method of the composite gel is correspondingly adjusted.
Comparative example 2
Compared with the embodiment 2, the composite gel has the advantages that the gamma-polyglutamic acid is replaced by the same amount of sodium alginate, namely the gamma-polyglutamic acid is not contained, the amount of the sodium alginate is 8g, other components and the content are not changed, and the preparation method of the composite gel is correspondingly adjusted.
Comparative example 3
Compared with the compound gel in the embodiment 1, the bacteriostatic agent is an N-acetylmuramyl glycan hydrolase-Arabic gum compound, sclerotium rolfsii gum is replaced by Arabic gum in the preparation method of the bacteriostatic agent, and other components, contents and the preparation method of the compound gel are unchanged.
Comparative example 4
The composite gel is prepared from the following raw materials in mass number: 1g of sodium alginate, 0.2g of N-acetylmuramic polysaccharide hydrolase, 0.4g of sclerotium rolfsii gum, 8g of gamma-polyglutamic acid (the relative molecular weight is 50 ten thousand), 1g of honey, 1.7g of carbomer, 9g of sorbitol, 2g of pH regulator and 100g of deionized water.
The preparation method of the composite gel comprises the following steps:
s1: taking a proper amount of deionized water, uniformly scattering 1.7g of carbomer powder while stirring, standing, and naturally swelling for 24 hours to obtain a carbomer solution;
s2: respectively dissolving 1g of sodium alginate, 8g of gamma-polyglutamic acid, 0.2g of N-acetylmuramic polysaccharide hydrolase and 0.4g of sclerotinia sclerotiorum by using a proper amount of deionized water, then mixing with the carbomer solution obtained from S1, adding 9g of sorbitol, 1g of honey and the balance of deionized water, stirring uniformly and defoaming under a vacuum condition, and adjusting the pH to 5.5-7.0 by using a pH regulator to obtain a sodium alginate composite gel raw material solution;
s3: defoaming and molding the composite gel raw material liquid obtained in the step S2 at a dosage of 10kGy60And (3) carrying out irradiation crosslinking under Co-gamma rays, and cutting to obtain the sodium alginate composite gel with the thickness of 0.1 cm.
Comparative example 5
Compared with the compound gel in the embodiment 2, the honey is replaced by the same amount of the gamma-polyglutamic acid, namely the compound gel does not contain the honey, the gamma-polyglutamic acid accounts for 3g, other components and contents are not changed, and the preparation method of the compound gel is correspondingly adjusted.
Comparative example 6
Compared with the compound gel in the embodiment 3, the bacteriostatic agent is replaced by the same amount of honey, namely the compound gel does not contain the bacteriostatic agent, 5.2g of honey is kept, other components and content are not changed, the preparation method of the bacteriostatic agent is omitted, and the preparation method of the compound gel is correspondingly adjusted.
Efficacy test 1 swellability test
The composite gels of examples 1 to 4 of the present invention and comparative examples 1 and 2 were subjected to a swelling test:
respectively shearing a piece of composite gel with the same size, drying, weighing, and recording the mass as MdPutting the gel core in a beaker, adding enough water, completely immersing the gel core, clamping the dressing with forceps after the gel core fully absorbs moisture, absorbing the surface moisture with filter paper, weighing, and recording as Ms.
The gel swelling property calculation formula is as follows:
Swelling＝(Ms-Md)/Md
Md: weight of gel after drying;
ms: weight of gel at swelling equilibrium.
TABLE 1 composite gel swelling test results
| Sample specimen | Md(g) | Ms(g) | Multiple of liquid absorption |
| Example 1 | 2.53 | 27.88 | 11.02 |
| Example 2 | 2.61 | 30.34 | 11.62 |
| Example 3 | 2.54 | 32.89 | 12.95 |
| Example 4 | 2.46 | 35.52 | 14.44 |
| Comparative example 1 | 2.75 | 24.63 | 8.96 |
| Comparison ofExample 2 | 2.68 | 25.45 | 9.50 |
As can be seen from the results of table 1, the sodium alginate complex gel of the present invention exhibited good swelling properties, which are derived from the fact that both sodium alginate and gamma-polyglutamic acid are hydrophilic polymers. The swelling performance of comparative examples 1 and 2 is lower than that of examples 1-4, which shows that when the sodium alginate and the gamma-polyglutamic acid are compounded, the swelling performance of the compound gel can be effectively improved, so that the gel has a better absorption and permeation effect.
Efficacy test 2 bacteriostatic activity test
The composite dressings of example 1 and comparative examples 3 and 4 were sampled, cut into a size of 1.0cm × 1.0cm, placed in a 250mL Erlenmeyer flask, 70mL of PBS and 5mL of bacterial suspension were added, respectively, and the concentration of bacterial suspension in PBS was adjusted to 4 × 104-6×104CFU/mL, the Erlenmeyer flask fixed on the shaking table, at 150r/min after shaking for 24h, respectively sampling liquid, PBS appropriate dilution, agar pouring method inoculation plate, colony count. The bacteriostasis rate is the ratio (in percentage) of the difference of the average colony number of the tested sample before and after oscillation to the average colony number of the sample before oscillation. The strain is selected from Escherichia coli and Staphylococcus aureus.
As can be seen from the results of the accompanying drawings 1 and 2, the sodium alginate composite gel of the embodiment 1 of the invention can effectively inhibit escherichia coli and staphylococcus aureus, the inhibition rate of escherichia coli on the 3 rd day is 100%, and the inhibition rate of staphylococcus aureus on the 5 th day is 100%.
Comparative example 3 compared with example 1, the antibacterial agent used in comparative example 3 was N-acetylmuramyl polysaccharide hydrolase-gum arabic complex, which had a lower inhibitory effect against E.coli and Staphylococcus aureus than the sodium alginate complex gel of example 1. Compared with the example 1, the sodium alginate composite gel of the comparative example 4 is directly added with the N-acetylmuramyl polysaccharide hydrolase and the sclerotium rolfsii gum, the sodium alginate composite gel of the example 1 is added with the N-acetylmuramyl polysaccharide hydrolase-sclerotium rolfsii gum compound prepared by a specific reaction, and the results of the figure 1 and the figure 2 show that the N-acetylmuramyl polysaccharide hydrolase-sclerotium rolfsii gum compound accelerates the death of escherichia coli and staphylococcus aureus and has better bacteriostatic action.
Efficacy test 3 healing promotion test
Taking 45 male New Zealand rabbits, 2-3 kg of each rabbit, and randomly dividing the rabbits into 9 groups, 5 rabbits each group. The rabbits all cause 30% TBSA shallow II degree burns according to a preparation method of a clinical animal experiment burn standard model, wherein the rabbits in the group A do not use any dressing, B, C, D, E groups respectively use the sodium alginate composite gel of the invention in the examples 1-4, F, G, H, I groups respectively use the composite gels of the comparative examples 1, 2, 5 and 6, and the replacement is carried out twice a day. The specific test results are shown in Table 2.
TABLE 2 infection and healing (%)
From the results of animal experiments, after the wounds of the rabbits in the B-E group are applied with respective gels, the wounds have no infection phenomenon and no red swelling, and secretions disappear in about 3 days. On the other hand, the healing time of the rabbit wound of the B-E group is obviously shorter than that of the rabbit wound of the A group, and the time difference has obvious significance. The sodium alginate composite gel has better functions of absorbing and permeating, inhibiting bacteria and promoting healing.
The I group of rabbits have more infections, which shows that when the sodium alginate composite gel does not contain bacteriostatic agents and only contains honey, the bacteriostatic performance is obviously reduced. F. G, H, I group of rabbits applied with the dressing respectively has healing time and secretion disappearance time higher than those of B-E group of rabbits, which shows that the sodium alginate, bacteriostatic agent, gamma-polyglutamic acid, honey and other components in the sodium alginate composite gel are synergistic, and the combination of various natural source components improves the functions of absorption, permeation, bacteriostasis and healing promotion of the gel.
While specific embodiments of the present invention have been described above, the present invention is not limited to the above embodiments, and various modifications can be made within the scope of the technical gist of the present invention in the technical field of the present invention, as long as the general knowledge is grasped.
Claims (7)
1. The sodium alginate composite gel is characterized by being prepared from the following raw materials in percentage by mass: 1-8% of sodium alginate, 0.2-1% of bacteriostatic agent, 1-8% of gamma-polyglutamic acid, 1-5% of honey, 0.1-2% of carbomer, 1-16% of sorbitol, 0.1-2.5% of pH regulator and the balance of deionized water.
2. The sodium alginate complex gel as claimed in claim 1, wherein the bacteriostatic agent is N-acetylmuramyl polysaccharide hydrolase-sclerotium rolfsii complex.
3. The sodium alginate complex gel as claimed in claim 1, wherein the relative molecular weight of the gamma-polyglutamic acid is between 50 and 150 ten thousand.
4. The sodium alginate composite gel as claimed in claim 1, wherein the thickness of the sodium alginate composite gel is 0.1-0.5 cm.
5. The sodium alginate composite gel as claimed in claim 2, wherein the preparation method of the bacteriostatic agent is as follows: mixing N-acetylmuramic polysaccharide hydrolase and sclerotium rolfsii gum according to the weight ratio of 1: 2-1: 4 to obtain a mixture, dissolving the mixture in a sodium phosphate buffer solution with the concentration of 0.1mol/L, pH of 8.0-9.0, wherein the weight-volume ratio of the mixture to the sodium phosphate buffer solution is 1 (10-20) g/mL, incubating for 1h at room temperature, freeze-drying at-70 ℃, placing the freeze-dried sample in a sealed glass dryer with a saturated KBr solution at the bottom, and placing for 8-12 days at the temperature of 60 ℃ and the relative humidity of 80% to obtain the N-acetylmuramic polysaccharide hydrolase-sclerotium rolfsii gum compound.
6. The preparation method of sodium alginate complex gel as claimed in any one of claims 1 to 5, which is characterized by comprising the following steps:
s1: taking a proper amount of deionized water, uniformly scattering carbomer powder while stirring, standing, and naturally swelling for 24 hours to obtain a carbomer solution;
s2: respectively dissolving sodium alginate, gamma-polyglutamic acid and a bacteriostatic agent by using a proper amount of deionized water, then mixing with the carbomer solution obtained in S1, adding sorbitol, honey and the balance of deionized water, stirring uniformly under a vacuum condition, defoaming, and adjusting the pH to 5.5-7.0 by using a pH regulator to obtain a sodium alginate composite gel raw material solution;
s3: and (5) defoaming, injection molding, irradiation crosslinking and cutting the composite gel raw material liquid obtained in the step (S2) to obtain the sodium alginate composite gel.
7. The method for preparing sodium alginate composite gel as claimed in claim 6, wherein the irradiation crosslinking mode in step S3 is adopted60And irradiating the Co-gamma rays or the high-energy electron beams with the irradiation dose of 10-50 kGy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011169853.XA CN112336914B (en) | 2020-10-28 | 2020-10-28 | Sodium alginate composite gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011169853.XA CN112336914B (en) | 2020-10-28 | 2020-10-28 | Sodium alginate composite gel and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112336914A true CN112336914A (en) | 2021-02-09 |
| CN112336914B CN112336914B (en) | 2022-10-14 |
Family
ID=74358830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011169853.XA Expired - Fee Related CN112336914B (en) | 2020-10-28 | 2020-10-28 | Sodium alginate composite gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112336914B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113318233A (en) * | 2021-04-30 | 2021-08-31 | 杭州爱光医疗器械有限公司 | Temperature-sensitive gynecological bacteriostatic liquid composition and preparation method thereof |
| CN114306180A (en) * | 2021-12-18 | 2022-04-12 | 中国人民解放军空军军医大学 | Ultraviolet sunburn repairing agent capable of being placed for long time and preparation method thereof |
| CN114835920A (en) * | 2022-05-20 | 2022-08-02 | 湖南科妍创美医疗科技有限公司 | Recombinant collagen-polyglutamate hydrogel and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120301436A1 (en) * | 2011-05-27 | 2012-11-29 | Taipei Medical University | Polyelectrolyte complex gels and soft tissue augmentation implants comprising the same |
| CN104788686A (en) * | 2015-04-17 | 2015-07-22 | 兰州理工大学 | Method of covalent compound modification of potato protein and polysaccharide |
| CN105169464A (en) * | 2015-09-24 | 2015-12-23 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Natural honey wound dressing and preparing method and application thereof |
| CN106492260A (en) * | 2016-12-22 | 2017-03-15 | 青岛琛蓝海洋生物工程有限公司 | A kind of alginate based aquagel dressing and preparation method thereof |
| CN109354702A (en) * | 2018-10-23 | 2019-02-19 | 东北农业大学 | High swelling property bean dregs Process for preparing hydrogels |
-
2020
- 2020-10-28 CN CN202011169853.XA patent/CN112336914B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120301436A1 (en) * | 2011-05-27 | 2012-11-29 | Taipei Medical University | Polyelectrolyte complex gels and soft tissue augmentation implants comprising the same |
| CN104788686A (en) * | 2015-04-17 | 2015-07-22 | 兰州理工大学 | Method of covalent compound modification of potato protein and polysaccharide |
| CN105169464A (en) * | 2015-09-24 | 2015-12-23 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Natural honey wound dressing and preparing method and application thereof |
| CN106492260A (en) * | 2016-12-22 | 2017-03-15 | 青岛琛蓝海洋生物工程有限公司 | A kind of alginate based aquagel dressing and preparation method thereof |
| CN109354702A (en) * | 2018-10-23 | 2019-02-19 | 东北农业大学 | High swelling property bean dregs Process for preparing hydrogels |
Non-Patent Citations (3)
| Title |
|---|
| HUANG MH等: ""Swelling and biocompatibility of sodium alginate/poly(γ-glutamic acid) hydrogels"", 《POLYMERS FOR ADVANCED TECHNOLOGIES》 * |
| 张俊著: "《绿色络合催化》", 30 November 2009, 甘肃文化出版社 * |
| 董祥忠主编: "《现代塑料成型工程》", 30 September 2009, 国防工业出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113318233A (en) * | 2021-04-30 | 2021-08-31 | 杭州爱光医疗器械有限公司 | Temperature-sensitive gynecological bacteriostatic liquid composition and preparation method thereof |
| CN114306180A (en) * | 2021-12-18 | 2022-04-12 | 中国人民解放军空军军医大学 | Ultraviolet sunburn repairing agent capable of being placed for long time and preparation method thereof |
| CN114306180B (en) * | 2021-12-18 | 2023-08-29 | 中国人民解放军空军军医大学 | Ultraviolet sunburn repairing agent capable of being placed for long time and preparation method thereof |
| CN114835920A (en) * | 2022-05-20 | 2022-08-02 | 湖南科妍创美医疗科技有限公司 | Recombinant collagen-polyglutamate hydrogel and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112336914B (en) | 2022-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112336914B (en) | Sodium alginate composite gel and preparation method thereof | |
| Singh et al. | Radiation synthesis of PVP/alginate hydrogel containing nanosilver as wound dressing | |
| CN101278896B (en) | Chitosan nano silver gel agent and uses thereof | |
| CN105012993A (en) | Medical and antibacterial cationic biogel dressing and preparation method thereof | |
| CN113842497B (en) | Preparation method of CuS @ Cur hybrid hydrogel dressing with light-operated antibacterial and self-healing functions | |
| CN112451738B (en) | Silver ion polysaccharide polymer antibacterial dressing and preparation method and application thereof | |
| CN105228658A (en) | A kind of medical dressing hydrogel compound fabric and its preparation method and application | |
| TWI814462B (en) | Manufacturing method of hemostatic material and hemostatic material prepared thereby | |
| Jiang et al. | Carboxymethyl chitosan-based multifunctional hydrogels incorporated with photothermal therapy against drug-resistant bacterial wound infection | |
| CN111068103B (en) | Long-acting antibacterial gel dressing for operation wound and preparation method thereof | |
| CN112587719A (en) | Antibacterial hemostatic membrane and preparation method and application thereof | |
| CN106344954A (en) | Bio-antimicrobial bacterial cellulose dressing and preparation method thereof | |
| CN111643724A (en) | Preparation method and application of hydrogel wound dressing loaded with bacteriophage and acidic fibroblast growth factor | |
| CN113018499A (en) | Preparation method of ozone oil-water gel composite application capable of sterilizing, resisting virus and absorbing moisture | |
| CN117257721A (en) | Antibacterial peptide-loaded multifunctional gel and preparation method and application thereof | |
| CN115624647B (en) | Biological film medical dressing compounded with wound healing medicine and film essence, and preparation method and application thereof | |
| CN109432483B (en) | Medical dressing for accelerating wound healing and preparation method and application thereof | |
| US3804949A (en) | Process of promoting healing of wounds | |
| CN107185026B (en) | Preparation method of medical konjac glucomannan antibacterial dressing | |
| CN110917339B (en) | Lysostaphin gel and application thereof in MRSA (tissue-specific respiratory tract infection) wound surface | |
| CN111803696B (en) | Preparation method of patchouli oil nano composite membrane for skin wound repair | |
| RU2545735C1 (en) | Bioactive hydrogel wound coating | |
| CN110433134B (en) | Nitric oxide releasing ointment and preparation method and application thereof | |
| CN112426562A (en) | Pure natural medical dressing for promoting wound healing | |
| RU2270646C2 (en) | Dressing material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20221014 |